Clareo Health | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
This is a multicenter, open-label, Phase 1/2 study to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of MEDI0680 in combination with durvalumab or nivolumab monotherapy in adult immunotherapy-naïve participants with selected advanced malignancies.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must be 18 years or older
Eastern Cooperative Oncology Group performance status of 0-1
Adequate organ function
At least 1 prior line of therapy
You may not be if
Concurrent enrollment in another clinical study, unless in follow-up period or it is an observational study
Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
